Research location
Hamm
North Rhine-Westphalia, Germany
Advertisement
Research activity in Hamm
North Rhine-Westphalia, GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 15 trials and 15 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Hamm
15 linked trials · page 1 of 1Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBCNCT07242352 · 2026-04-29 · 1 site observation
RECRUITING
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)NCT06081244 · 2024-10-10 · 1 site observation
RECRUITING
NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast CancerNCT05704829 · 2024-02-05 · 1 site observation
RECRUITING
PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFSNCT05792150 · 2022-12-07 · 1 site observation
RECRUITING
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerNCT07178730 · 2026-08-30 · 1 site observation
NOT_YET_RECRUITING
Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation (DigiNet)NCT05818449 · 2022-06-01 · 1 site observation
UNKNOWN
Real-life Pan-HER-blockade With NeratinibNCT04388384 · 2020-07-02 · 1 site observation
COMPLETED
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBCNCT04055493 · 2019-07-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)NCT03976375 · 2019-06-26 · 1 site observation
COMPLETED
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)NCT03924869 · 2019-06-25 · 1 site observation
TERMINATED
A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibNCT03535740 · 2019-01-31 · 1 site observation
COMPLETED
Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast CancerNCT01891357 · 2013-09-30 · 1 site observation
TERMINATED
Dose-ranging Study of Vilanterol (VI) Inhalation Powder in ChildrenNCT01573767 · 2012-04-01 · 1 site observation
COMPLETED
A Dose-ranging Study of Fluticasone Furoate (FF)NCT01563029 · 2012-03-28 · 1 site observation
COMPLETED
Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung CancerNCT00320359 · 2002-08-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.